You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations.
The Warsaw, Poland-based firm has secured nearly €20 million ($23.7 million) this year to advance its PCR One point-of-care molecular diagnostic system.
Exome array-wide association and rare variant-focused genome-wide association meta-analyses led to 87 rare variants with ties to one or more blood pressure traits.
The firm said the funding will support the launch of its miniaturized ELISA platform, which reduces the time and sample volume required for such assays.
Total fiscal fourth quarter revenues more than doubled while the synthetic DNA maker's fiscal 2020 revenues grew 66 percent to $90.1 million.
The partnership goes hand-in-hand with Genentech's new precision basket trial, for which it will identify and enroll patients across OneOncology's network.
The Temple City, California-based firm has raised its full-year guidance for the third time this year and now expects 2020 revenues of $300 million.
The company stock will now trade on a split-adjusted basis on the Nasdaq after reducing its number of shares from 200 million to 26.7 million.
The kit is designed for use with samples stored in the company's CE-marked DNA/RNA Shield sample collection and preservation devices.
William Blair, Canaccord Genuity, and BTIG on Monday initiated coverage of newly public Biodesix, with ratings ranging from Buy to Outperform.
The firms said that the test would help Siolta identify and monitor patients eligible for its biotherapeutic therapy currently under development.
The regulatory submission triggers a milestone payment, and Invitae will issue 5 million shares of its common stock to former ArcherDx securityholders.
News items for the week of Nov. 16, 2020.
The company reported total revenues of RMB123.9 million ($18.2 million) for the quarter, driven largely by growth in its central laboratory business.
The company said that its Aptima HIV-1 molecular test utilizes a dual-target approach against highly conserved regions in the HIV genome.
The firm CE marked its RespiFinder 2Smart kit for SARS-CoV-2 and MERS-CoV testing, as well as the RealAccurate Quadriplex Flu/COVID-19 PCR kit.
The company's AlloSure Kidney test received coverage, along with its AlloSure Heart test when used with the firm's AlloMap test.
Illumina Ventures led the round for the Santa Clara, California-based firm, which is developing applications for its optical detection technology.
Aspira said it will bring its experience in patient sample recruitment and ovarian cancer assay development to the collaboration.
Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.
The firm said it will dispute the claim of overpayment and will separately negotiate with the undisclosed payor for in-network status.
The test will identify patients with squamous cell head and neck cancer caused by specific HPV infections for treatment with BioNTech's investigational BNT113.
The atlas further enabled researchers to uncover the molecular state of cells, identify the targets of circulating hormones, and determine the cells affected by disease genes or viruses.
NPR reports the US Food and Drug Administration has approved a treatment for a genetic disorder that causes rapid aging.
Late-stage testing indicates the AstraZeneca and Oxford University SARS-CoV-2 vaccine can have up to 90 percent efficacy, the Associated Press reports.
ScienceInsider reports Nature Communications is reviewing a paper on mentorship following social media criticism arguing it is sexist.
In PLOS this week: method to account for sequencing errors in phylogenies, study of influenza A in Switzerland, and more.